Company / Operating Cash Flow
Theravance Biopharma, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$238.5M
FY2025
5-year range
-$250.4M / $238.5M
FY2021-FY2025
Trend
+2168.0%
vs FY2024
Sector context
#36 of 216
Health Care
What the data says
Operating Cash Flow changed +2168% YoY in FY2025, a notable deviation from the 9-year average annual change of +237%.
Based on SEC 10-K filings.
$239M in FY2025. Top quartile in the Health Care sector.
Improved from -$27M to $239M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 216This company $238.5M Sector average $658.7M
▼
-63.8% below sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 2168.0% year-over-year.
- Ranks #36 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $238.5M | +2168.0% |
| FY2024 | -$11.5M | +57.3% |
| FY2023 | -$27.0M | +89.2% |
| FY2022 | -$250.4M | -20.5% |
| FY2021 | -$207.9M | +17.0% |
| FY2020 | -$250.4M | -24.5% |
| FY2019 | -$201.1M | -103.1% |
| FY2018 | -$99.0M | +50.8% |
| FY2017 | -$201.1M | -103.1% |
| FY2016 | -$99.0M | +18.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026